Cas:10314-35-9 N-cyclohexylsulfamoyl chloride manufacturer & supplier

Chemical Name:N-cyclohexylsulfamoyl chloride

CAS.NO:10314-35-9

Synonyms:cyclohexylsulfamyl chloride;cyclohexylsulfamoyl chloride;Sulfamoyl chloride,cyclohexyl;cyclohexylaminosulfonyl chloride;cyclohexylsulfamic acid chloride

Molecular Formula:C₆H₁₂ClNO₂S

Molecular Weight:197.68300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:54.55000

Exact Mass:197.02800

LogP:2.86400

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like cyclohexylsulfamyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cyclohexylsulfamic acid chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Sulfamoyl chloride,cyclohexyl Use and application,cyclohexylsulfamyl chloride technical grade,usp/ep/jp grade.

Related News: China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. N-cyclohexylsulfamoyl chloride manufacturer Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. N-cyclohexylsulfamoyl chloride supplier As you can see, a considerable number of staff is involved in the production phase until an API is finally manufactured. N-cyclohexylsulfamoyl chloride vendor The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15. N-cyclohexylsulfamoyl chloride factory China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.